WAT Medical will attend 2020 CES to exhibit their innovative wearable technologies: EmeTerm, the anti-vomiting wrist band, and HeadaTerm, the anti-migraine head patch

December 20, 2019
WAT Medical

WAT Medical is a Canadian company that develops safe, effective, and user-friendly wearable medical devices. They focus on chronic and functional diseases and conditions. Their technologies use targeted neuromodulation to regulate specific nerve activities. The treatments are patient-oriented, with fixed parameters for individual conditions, and features excellent usability. Customers will receive personalized therapies according to … Continue reading WAT Medical will attend 2020 CES to exhibit their innovative wearable technologies: EmeTerm, the anti-vomiting wrist band, and HeadaTerm, the anti-migraine head patch

Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock

December 17, 2019
Neoleukin Therapeutics, Inc.

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that it intends to offer and sell, subject to market and other conditions, up to $50.0 million of shares of its common stock in an underwritten public offering.  Neoleukin expects to grant the underwriters a 30-day … Continue reading Neoleukin Therapeutics Announces Proposed Public Offering of Common Stock

Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering

SEATTLE, Dec. 17, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the pricing of an underwritten public offering of 8,925,000 shares of its common stock at a price to the public of $8.40 per share. The aggregate gross proceeds from this offering are expected to be … Continue reading Neoleukin Therapeutics Announces Pricing of $75.0 Million Public Offering

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

December 12, 2019
InMed Pharmaceuticals Inc.

Vancouver, BC – December 9, 2019 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage biopharmaceutical company developing cannabinoid-based medications targeting diseases with high unmet medical needs, today announced it has received regulatory and ethics board approval of its Clinical Trial Application (“CTA”) to conduct a Phase 1 trial in the … Continue reading InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Aurinia Pharmaceuticals Inc.

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, today announced the closing of its previously announced underwritten public offering of 12,782,439 common shares, including 1,667,274 common shares pursuant to the full exercise of the underwriters’ option to purchase … Continue reading Aurinia Closes US$191.7 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

December 9, 2019
Xenon Pharmaceuticals Inc.

Overview of Clinical Stage XEN901 and Related Patient Survey to be Presented in the “Genetic Epilepsies – Updates in the Science and Diagnosis” Exhibit in Room 318-319 on Sunday, December 8th Pre-Clinical Work Suggests Selective Sodium Channel Inhibitors that Reduce Action Potential Firing in Excitatory Neurons, While Sparing Inhibitory Interneurons, May Provide Promising Drug Profile … Continue reading Xenon Pharmaceuticals Provides Updates on Partnered Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Dr. Stirling Bryan announced as BC AHSN President as of January 2020

December 6, 2019
British Columbia Academic Health Science Network (BC AHSN)

Vancouver, Canada (December 6th, 2019) – The board of directors of the British Columbia Academic Health Science Network (BC AHSN) is pleased to announce that Dr. Stirling Bryan has been named the President of the organization as of January 1st, 2020. He replaces Dr. Tom Noseworthy as the organization’s leader; Dr. Noseworthy’s term of office … Continue reading Dr. Stirling Bryan announced as BC AHSN President as of January 2020

Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Xenon Pharmaceuticals Inc.

Xenon’s Epilepsy Programs Continue to Advance Including Ongoing XEN1101 Phase 2b Clinical Trial in Adult Focal Epilepsy and Plans for Anticipated Pediatric XEN496 Pivotal Phase 3 Clinical Trial in KCNQ2-DEE Patients Promising New Pre-Clinical Data Support Precision Medicine Approach to Treat Dravet Syndrome with Highly Selective Potentiators of Nav1.1 Xenon Extends Invitation to View its … Continue reading Xenon Pharmaceuticals Provides Updates on Proprietary Neurology Pipeline Programs at the 2019 American Epilepsy Society (AES) Annual Meeting

Neoleukin Therapeutics Announces Scientific Advisory Board

December 5, 2019
Neoleukin Therapeutics, Inc.

Preeminent leaders in protein design, structural biology and immunology SEATTLE, Dec. 05, 2019 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc. “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the formation of a Scientific Advisory Board comprised of leaders in the fields of de novo protein design, structural biology and immunology. “This distinguished group of scientific leaders will … Continue reading Neoleukin Therapeutics Announces Scientific Advisory Board

Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis

Aurinia Pharmaceuticals

Voclosporin achieved statistically superior Renal Response rate (p < 0.001) and comparable safety profile versus standard of care – – Statistically significant results demonstrated in all pre-specified hierarchical secondary endpoints – – Aurinia plans to file an NDA submission to the FDA during the first half of 2020 – – Company to host conference call … Continue reading Aurinia Announces Positive AURORA Phase 3 Trial Results Demonstrating Voclosporin Superiority Over Standard of Care in Lupus Nephritis